WALTHAM, Mass.--(BUSINESS WIRE)--June 5, 2006--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN): OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a leading developer of biopharmaceutical compounds designed to treat cancer and certain ophthalmologic diseases, today announced new, positive data from two Phase II clinical trials that suggest the therapeutic potential of its lead therapeutic compound under development, CA4P, in the treatment of Anaplastic Thyroid Cancer (ATC). The separate trials show patient response, as well as the biological activity of CA4P when CA4P is used either in combination with chemotherapy or as a monotherapy.
